Drugs, the use of which is associated with the development of drug-induced kidney stone disease. Part 2


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Kidney stone disease (KSD) is a significant pathology in clinical practice. One of the most important causes of stone formation are drugs. Drugs lead to drug-induced (DI) KSD by crystallization in the urine and influence on various metabolic processes. Among the drugs capable of crystallization, it is necessary to note antibacterial drugs. KSD inducers from this group include aminopenicillins, quinolones and ceftriaxone. The most important risk factor for nephrolithiasis while taking antibacterial drugs is their use in high doses. In addition to drugs that crystallize in the urine, drugs that affect various metabolic processes play an important role as inducers of KSD. These include calcium supplements, vitamin D and C supplements, and carbonic anhydrase inhibitors. The role of the mentioned additives as inducers of urolithiasis can be underestimated due to their widespread use, including without a doctor’s prescription. Pediatric practice also describes the processes of stone formation against the background of the use of furosemide. It is also necessary to note allopurinol, the mechanism of lithogenesis against the background of which is mixed. The uniqueness of this review is that data on inducer drugs were combined from various sources and structured according to a single plan.

Full Text

Restricted Access

About the authors

A. I Listratov

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

Olga D. Ostroumova

Russian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: ostroumova.olga@mail.ru
Dr. Sci. (Med.), Professor, Head of Department of Therapy and Polymorbid Pathology n.a. Academician M.S. Vovsi; Professor at Department of Clinical Pharmacology and Propedeutics of Internal Diseases Moscow, Russia

N. L Lyakhova

Botkin City Clinical Hospital of the Moscow Department of Health

Moscow, Russia

References

  1. Клинические рекомендации. Мочекаменная болезнь. Минздрав России, Общероссийская общественная организация «Российское общество урологов». Пересмотр 2020 г. URL: https://cr.minzdrav.gov.ru/recomend/7_1
  2. Daudon M, Frochot V, Bazin D., Jungers P Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Drugs. 2018;78(2):163-201. doi: 10.1007/s40265-017-0853-7.
  3. Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004;64(3):245-75. doi: 10.2165/00003495200464030-00003.
  4. Ulinski T, Sabot J.F., Bourlon I., Cochat P Bilateral urinary calculi after treatment with a silicate-containing milk thickener. EurJ Pediatr. 2004;163(4-5):239-40. doi: 10.1007/s00431-004-1400-6.
  5. Montagnac R., Briat C., Schillinger F, et al. Fluoroquinolone induced acute renal failure. General review about a case report with crystalluria due to ciprofloxacin. Nephrol Ther. 2005;1(1):44-51. French. doi: 10.1016/j.nephro.2005.02.005.
  6. Sedlacek M, Suriawinata A.A., Schoolwerth A., Remillard B.D. Ciprofloxacin crystal nephropathy -a ‘new' cause of acute renal failure. Nephrol Dial Transplant. 2006;21(8):2339-40. Doi: 10.1093/ ndt/gfl160.
  7. Khan M, Ortega L.M., Bagwan N., Nayer A. Crystal-induced acute kidney injury due to ciprofloxacin. J Nephropathol. 2015;4(1):29-31. Doi: 10.12860/ jnp.2015.06.
  8. Dobrek t. Kidney stone disease with special regard to drug-induced kidney stones - a contemporary synopsis. Wiad Lek. 2020;73(9 cz. 2):2031-39. doi: 10.36740/WLek202009226.
  9. Wiseman L.R., Balfour J.A. Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging. 1994;4(2):145-73. doi: 10.2165/00002512-199404020-00007.
  10. Thorsteinsson S.B., Bergan T., Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy. 1988;34(3):256-60. doi: 10.1159/000238577.
  11. Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem. 1986;24:767-68.
  12. Chutipongtanate S., Thongboonkerd V. Ceftriaxone crystallization and its potential role in kidney stone formation. Biochem Biophys Res Commun. 2011;406(3):396-402. Doi: 10.1016/j. bbrc.2011.02.053.
  13. de Moor R.A., Egberts A.C., Schröder C.H. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr. 1999;158(12):975-77. Doi: 10.1007/ s004310051261.
  14. Zhang Y, Ning B., Zhu H., et al. Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review.Int Urol Nephrol. 2016;48(7):1061-69. Doi: 10.1007/ s11255-016-1273-4.
  15. Dichiara A.J., Atkinson M., Goodman Z., Sherman K.E. Ciprofloxacin-induced acute cholestatic liver injury and associated renal failure. Case report and review. Minerva Gastroenterol Dietol. 2008;54(3):307-15.
  16. Garnier A.S., Dellamaggiore J., Brilland B., et al. High Incidence of Amoxicillin-Induced Crystal Nephropathy in Patients Receiving High Dose of Intravenous Amoxicillin. J Clin Med. 2020;9(7):2022. doi: 10.3390/jcm9072022.
  17. Fogazzi G.B., Cantu M., Saglimbeni L., Daudon M. Amoxycillin, a rare but possible cause of crystalluria. Nephrol Dial Transplant. 2003;18(1):212-14. doi: 10.1093/ndt/18.1.212.
  18. Assimos D.G., Langenstroer P, Leinbach R.F, et al. Guaifenesin- and ephedrine-induced stones. J Endourol. 1999;13(9):665-67. Doi: 10.1089/ end.1999.13.665.
  19. Small E., Sandefur B.J. Acute renal failure after ingestion of guaifenesin and dextromethorphan. J Emerg Med. 2014;47(1):26-9. Doi: 10.1016/j. jemermed.2014.01.022.
  20. Song G.Y, Lockhart M.E., Smith J.K., et al. Pseudoephedrine and guaifenesin urolithiasis: widening the differential diagnosis of radiolucent calculi on abdominal radiograph. Abdom. Imaging. 2005;30(5):644-46. doi: 10.1007/s00261-004-0294-0.
  21. Gabardi S., Carter D., Martin S., Roberts K. Recommendations for the proper use of nonprescription cough suppressants and expectorants in solid-organ transplant recipients. Prog Transplant. 2011;21(1):6-13;quiz 14. doi: 10.7182/prtr.21.1.t837123h2350721j.
  22. Powell T., Hsu F.F., Turk J., Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. 1998;32(1):153-9. doi: 10.1053/ajkd.1998.v32.pm9669437.
  23. Blau J.J. Ephedrine nephrolithiasis associated with chronic ephedrine abuse. J Urol. 1998;160(3 Pt. 1):825. doi: 10.1097/00005392-199809010-00052.
  24. Bennett S., Hoffman N., Monga M. Ephedrine-and guaifenesin-induced nephrolithiasis. J Altern Complement Med. 2004;10(6):967-69. doi: 10.1089/acm.2004.10.967.
  25. Hoffman N., McGee S.M., Hulbert J.C. Resolution of ephedrine stones with dissolution therapy. J Urol. 2003;61(5):1035. doi: 10.1016/s0090-4295(02)02593-1.
  26. Perazella M.A. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459-65. doi: 10.1016/s0002-9343(99)00041-8.
  27. Yarlagadda S.G., Perazella M.A. Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf. 2008;7(2):147-58. doi: 10.1517/14740338.7.2.147.
  28. Hagos Y, Wolff N.A. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel). 2010;2(8):2055-82. doi: 10.3390/toxins2082055.
  29. Widemann B.C., Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703. Doi: 10.1634/ theoncologist.11-6-694.
  30. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-83. Doi: 10.1056/ NEJMoa055218.
  31. Lappe J., Watson P., Travers-Gustafson D., et al. Effect of vitamin D an calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA. 2017;317(12):1234-43. Doi: 10.1001/ jama.2017.2115.
  32. Hu H., Zhang J., Lu Y, et al. Association between Circulating Vitamin D Level and Urolithiasis: A Systematic Review and Meta-Analysis. Nutrients. 2017;9(3):301. doi: 10.3390/nu9030301.
  33. Pak C.Y., Sakhaee K., Hwang T.I., et al. Nephrolithiasis from calcium supplementation. J Urol. 1987;137(6):1212-13. doi: 10.1016/s0022-5347(17)44455-7.
  34. Molin A., BauDoin R., Kaufmann M., et al. CYP24A1 Mutations in a Cohort of Hypercalcemic Patients: Evidence for a Recessive Trait. J. Clin. Endocrinol. Metab. 2015;100(10):E1343-52. Doi: 10.1210/ jc.2014-4387.
  35. Alelign T, Petros B. Kidney Stone Disease: An Update on Current Concepts. Adv Urol. 2018;2018:3068365. doi: 10.1155/2018/3068365.
  36. Levine B.S., Rodman J.S., Wienerman S., et al. Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: implications for prevention of osteoporosis. Am J Ciin Nutr 1994;60(4):592-96. Doi: 10.1093/ ajcn/60.4.592.
  37. Harris S.S., Dawson-Hughes B. Effects of Hydration and Calcium Supplementation on Urine Calcium Concentration in Healthy Postmenopausal Women. J Am Coll Nutr. 2015;34(4):340-46. doi: 10.1080/07315724.2014.959207.
  38. Ferraro PM., Curhan G.C., Gambaro G., et al. Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones. Am J Kidney Dis. 2016;67(3):400-7. doi: 10.1053/j.ajkd.2015.09.005.
  39. Thomas L.D., Elinder C.G., Tiselius H.G., et al. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA.Intern Med. 2013;173(5):386-88. Doi: 10.1001/ jamainternmed.2013.2296.
  40. Hoffer L.J., Levine M., Assouline S., et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19(11):1969-74. Doi: 10.1093/ annonc/mdn377.
  41. Robitaille L., Mamer O.A., Miller W.H. Jr, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metab. 2009;58(2):263-69. doi: 10.1016/j.metabol.2008.09.023.
  42. rlsnet.ru (электронный ресурс). РЛС. Реестр лекарственных средств России. Ацетазоламид (доступ от 15.01.2022). URL: https://www.rlsnet.ru/mnn_index_id_872.htm.
  43. Daudon M., Jungers P. Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol. 2004;98(2):31-6. doi: 10.1159/000080261.
  44. Ahlstrand C., Tiselius H.G. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol. 1987;21(3):225-28. doi: 10.3109/00365598709180326.
  45. Higashihara E., Nutahara K., Takeuchi T., et al. Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate. J Urol. 1991;145(5):942-48. doi: 10.1016/s0022-5347(17)38496-3.
  46. Sakhaee K., Maalouf N.M., Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97(6):1847-60. Doi: 10.1210/ jc.2011-3492.
  47. Scozzafava A., Supuran C.T. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349-59. doi: 10.1007/978-94-007-7359-2_17.
  48. Maalouf N.M., Langston J.P, Van Ness PC., et al. Nephrolithiasis in topiramate users. Urol Res. 2011;39(4):303-7. doi: 10.1007/s00240-010-0347-5.
  49. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23(8):1765-73. doi: 10.1185/03007990 7X210499.
  50. Go T. Zonisamide Induces Crystalluria without Urinary pH Changes in Children and Young Adults. ISRN Neurol. 2013;2013:841902. doi: 10.1155/2013/841902.
  51. Sheth R.D. Metabolic concerns associated with antiepileptic medications. Neurol. 2004;63(10 Suppl. 4):S24-9. doi: 10.1212/wnl.63.10_suppl_4.s24.
  52. Sato S., Nishinaka K., Takahashi S., et al. [Bilateral urolithiasis with zonisamide developed for a short period of time in a 10-year-old girl with intractable epilepsy]. Nihon Hinyokika Gakkai Zasshi. 2013;104(5):674-77. Japanese. Doi: 10.5980/ jpnjurol.104.674.
  53. Schell-Feith E.A., Kistvan Holthe J.E., van der Heijden A.J. Nephrocalcinosis in preterm neonates. Pediatr Nephrol. 2010;25(2):221-230. Doi: 10.1007/ s00467-008-0908-9.
  54. Gimpel C., Krause A., Franck P., et al. Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants. Pediatr Int. 2010;52(1):51-6. doi: 10.1111/j.1442-200X.2009.02886.x
  55. Mohamed G.B., Ibrahiem M.A., Abdel Hameed W.M. Nephrocalcinosis in pre-term neonates: a study of incidence and risk factors. Saudi J Kidney Dis Transpl. 2014;25(2):326-32. doi: 10.4103/13192442.128524.
  56. Kim Y.G., Kim B., Kim M.K., et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant. 2001;16(12):2303-309. Doi: 10.1093/ ndt/16.12.2303.
  57. Pacifici G.M. Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants. Paediatr Drugs. 2012;14(4):233-46. doi: 10.2165/11596620-000000000-00000.
  58. Blickman J.G., Herrin J.T., Cleveland R.H., Jaramillo D. Coexisting nephrolithiasis and cholelithiasis in premature infants. Pediatr Radiol. 1991;21(5):363-64. doi: 10.1007/BF02011489.
  59. Pattaragarn A., Fox J., Alon U.S. Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat. Kidney Int. 2004;65(5):1684-89. doi: 10.1111/j.1523-1755.2004.00564.x.
  60. Chu D.I., Tasian G.E., Copelovitch L. Pediatric Kidney Stones - Avoidance and Treatment. Curr Treat Options Pediatr. 2016;2(2):104-11. doi: 10.1007/s40746-016-0046-8.
  61. Hufnagle K.G., Khan S.N., Penn D., et al. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatr. 1982; 70(3):360-63.
  62. Alon U.S., Scagliotti D., Garola R.E. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr. 1994;125(1):149-51. doi: 10.1016/s0022-3476(94)70143-1.
  63. Ali S.K. Renal calculi complicating short-term furosemide therapy after congenital heart surgery. Congenit Heart Dis. 2006;1(5):251-53. doi: 10.1111/j.1747-0803.2006.00044.x.
  64. Torres R.J., Prior C., Puig J.G. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metab. 2007;56(9):1179-86. Doi: 10.1016/j. metabol.2007.04.013.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies